The inclusion of testing for EGFR gene polymorphisms in lung cancer screening programmes, especially for high-risk populations, can help in the early identification of individuals carrying unfavourable variants, and the adoption of targeted lifestyle modifications and regular surveillance to reduce the risk of morbidity. This evidence concerns the gene EGFR and lung cancer.